Allopurinol Modestly Cuts Death Risk With Hyperuricemia, Gout

Cohort study shows decline in all-cause mortality with allopurinol initiation

Allopurinol Modestly Cuts Death Risk With Hyperuricemia, Gout

MONDAY, March 31, 2014 (HealthDay News) -- Allopurinol initiation is associated with a modestly reduced risk of death in patients with hyperuricemia and gout, according to a study published online March 24 in the Annals of the Rheumatic Diseases.

Maureen Dubreuil, M.D., from the Boston University School of Medicine, and colleagues examined the impact of allopurinol initiation on the risk of mortality among individuals aged ≥40 years with hyperuricemia (serum urate level >357 µmol/L for women and >416 µmol/L for men). Propensity score-matched cohorts of allopurinol initiators (5,927 patients) and comparators (5,927 patients) were constructed.

The researchers found that 654 allopurinol initiators and 718 comparators died during a mean follow-up of 2.9 years. The two groups had similar baseline characteristics, including the prevalence of gout in each group (84 percent). There was a lower risk of all-cause mortality associated with allopurinol initiation (matched hazard ratio, 0.89). The corresponding hazard ratio was 0.81 when the analysis was limited to those with gout.

"The overall benefit of allopurinol on survival may outweigh the impact of rare serious adverse effects," the authors write.

Full Text (subscription or payment may be required)

Physician's Briefing